Literature DB >> 33864283

Magnetic resonance biomarkers in radiation oncology: The report of AAPM Task Group 294.

Kiaran P McGee1, Ken-Pin Hwang2, Daniel C Sullivan3, John Kurhanewicz4, Yanle Hu5, Jihong Wang6, Wen Li7, Josef Debbins8, Eric Paulson9, Jeffrey R Olsen10, Chia-Ho Hua11, Lizette Warner12, Daniel Ma13, Eduardo Moros14, Neelam Tyagi15, Caroline Chung6.   

Abstract

PURPOSE: A magnetic resonance (MR) biologic marker (biomarker) is a measurable quantitative characteristic that is an indicator of normal biological and pathogenetic processes or a response to therapeutic intervention derived from the MR imaging process. There is significant potential for MR biomarkers to facilitate personalized approaches to cancer care through more precise disease targeting by quantifying normal versus pathologic tissue function as well as toxicity to both radiation and chemotherapy. Both of which have the potential to increase the therapeutic ratio and provide earlier, more accurate monitoring of treatment response. The ongoing integration of MR into routine clinical radiation therapy (RT) planning and the development of MR guided radiation therapy systems is providing new opportunities for MR biomarkers to personalize and improve clinical outcomes. Their appropriate use, however, must be based on knowledge of the physical origin of the biomarker signal, the relationship to the underlying biological processes, and their strengths and limitations. The purpose of this report is to provide an educational resource describing MR biomarkers, the techniques used to quantify them, their strengths and weakness within the context of their application to radiation oncology so as to ensure their appropriate use and application within this field.
© 2021 American Association of Physicists in Medicine.

Entities:  

Keywords:  biomarker, imaging, MR, QIBA, quantitative, radiation therapy

Mesh:

Substances:

Year:  2021        PMID: 33864283      PMCID: PMC8361924          DOI: 10.1002/mp.14884

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  209 in total

1.  Contribution of vasogenic and cellular edema to traumatic brain swelling measured by diffusion-weighted imaging.

Authors:  P Barzó; A Marmarou; P Fatouros; K Hayasaki; F Corwin
Journal:  J Neurosurg       Date:  1997-12       Impact factor: 5.115

2.  1H-MRS in vivo predicts the early treatment outcome of postoperative radiotherapy for malignant gliomas.

Authors:  Rafal Tarnawski; Maria Sokol; Piotr Pieniazek; Boguslaw Maciejewski; Jerzy Walecki; Leszek Miszczyk; Teresa Krupska
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-04-01       Impact factor: 7.038

Review 3.  Tumor angiogenesis: pathophysiology and implications for contrast-enhanced MRI and CT assessment.

Authors:  C A Cuenod; L Fournier; D Balvay; J-M Guinebretière
Journal:  Abdom Imaging       Date:  2006 Mar-Apr

4.  Seizure disorders: functional MR imaging for diagnostic evaluation and surgical treatment--prospective study.

Authors:  L Santiago Medina; Byron Bernal; Catalina Dunoyer; Luisa Cervantes; Marelis Rodriguez; Esperanza Pacheco; Prasanna Jayakar; Glenn Morrison; John Ragheb; Nolan R Altman
Journal:  Radiology       Date:  2005-07       Impact factor: 11.105

5.  Quantification of cerebral metabolites in glioma patients with proton MR spectroscopy using T2 relaxation time correction.

Authors:  Tomonori Isobe; Akira Matsumura; Izumi Anno; Takashi Yoshizawa; Yasushi Nagatomo; Yuji Itai; Tadao Nose
Journal:  Magn Reson Imaging       Date:  2002-05       Impact factor: 2.546

6.  Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade.

Authors:  Meng Law; Stanley Yang; James S Babb; Edmond A Knopp; John G Golfinos; David Zagzag; Glyn Johnson
Journal:  AJNR Am J Neuroradiol       Date:  2004-05       Impact factor: 3.825

Review 7.  Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer.

Authors:  John V Hegde; Robert V Mulkern; Lawrence P Panych; Fiona M Fennessy; Andriy Fedorov; Stephan E Maier; Clare M C Tempany
Journal:  J Magn Reson Imaging       Date:  2013-05       Impact factor: 4.813

8.  Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Androgen Ablation Therapy in Prostate Cancer.

Authors:  Rahul Aggarwal; Daniel B Vigneron; John Kurhanewicz
Journal:  Eur Urol       Date:  2017-07-29       Impact factor: 20.096

9.  Integration of BOLD-fMRI and DTI into radiation treatment planning for high-grade gliomas located near the primary motor cortexes and corticospinal tracts.

Authors:  Minglei Wang; Hui Ma; Xiaodong Wang; Yanhong Guo; Xinshe Xia; Hechun Xia; Yulin Guo; Xueying Huang; Hong He; Xiaoxiong Jia; Yan Xie
Journal:  Radiat Oncol       Date:  2015-03-08       Impact factor: 3.481

10.  Model free approach to kinetic analysis of real-time hyperpolarized 13C magnetic resonance spectroscopy data.

Authors:  Deborah K Hill; Matthew R Orton; Erika Mariotti; Jessica K R Boult; Rafal Panek; Maysam Jafar; Harold G Parkes; Yann Jamin; Maria Falck Miniotis; Nada M S Al-Saffar; Mounia Beloueche-Babari; Simon P Robinson; Martin O Leach; Yuen-Li Chung; Thomas R Eykyn
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

View more
  2 in total

Review 1.  Virtual Biopsy in Soft Tissue Sarcoma. How Close Are We?

Authors:  Amani Arthur; Edward W Johnston; Jessica M Winfield; Matthew D Blackledge; Robin L Jones; Paul H Huang; Christina Messiou
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

Review 2.  MR-Guided Adaptive Radiotherapy for OAR Sparing in Head and Neck Cancers.

Authors:  Samuel L Mulder; Jolien Heukelom; Brigid A McDonald; Lisanne Van Dijk; Kareem A Wahid; Keith Sanders; Travis C Salzillo; Mehdi Hemmati; Andrew Schaefer; Clifton D Fuller
Journal:  Cancers (Basel)       Date:  2022-04-10       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.